Document 0784
 DOCN  M94B0784
 TI    Adoptive immunotherapy of cancer: a new approach for cancer treatment.
 DT    9412
 AU    Qin YC; Limburgs Universitair Centrum, Belgium
 SO    Diss Abstr Int [B]; 54(6):2983 1993. Unique Identifier : AIDSLINE
       ICDB/94605782
 AB    The conventional treatments of cancer are surgery, chemotherapy and
       radiotherapy. However, the therapeutic efficacy of these treatments are
       still far from satisfactory in most cases. With the development of
       immunology and increasing understanding in tumor immunology,
       immunotherapy has moved onto the stage of cancer treatments. Tumor
       infiltrating lymphocytes (TIL) therapy, as an adoptive immunotherapy
       form, has showed effectiveness in treating established lung and liver
       metastases in animal models. In preliminary human trials, 55% of the
       melanoma patients have responded to the TIL therapy. Studies have
       demonstrated that TIL are heterogeneous containing mostly CD3+ T cells
       with various amounts of CD4+ and CD8+ subsets, CD19+ B cells, CD16+ NK
       cells and other mononucleocytes. Functional study of TIL revealed that
       most of the T cell lines/clones derived from human breast tumor and
       melanoma tissues were cytotoxic as evaluated in lectin-dependent
       cytotoxicity assays which allow the detection of cytolytic T cells with
       any antigen specificity. Only a small portion of cytolytic T cells
       possess autologous tumor cell specificity. Analysis of T cell receptor
       of TIL lines/clones regarding DNA gene rearrangement and V beta gene
       expression suggest that an oligoclonal expansion of T cells might be
       present in tumor sites in encountering tumor antigen(s) or tumor
       associated antigen(s). The therapeutic efficacy of TIL therapy may be
       enhanced by cloning autologous tumor-specific T cells from tumor
       infiltrating lymphocytes, or by genetic manipulation to introduce new
       functional features to the TIL. (Full text available from University
       Microfilms International, Ann Arbor, MI, as Order No. AAD93-28553)
 DE    CD4-CD8 Ratio  Clinical Trials  Cytotoxicity, Immunologic  Human
       *Immunotherapy, Adoptive  Liver Neoplasms/SECONDARY/*THERAPY  Lung
       Neoplasms/SECONDARY/*THERAPY  Lymphocytes, Tumor-Infiltrating/IMMUNOLOGY
       Melanoma/IMMUNOLOGY/PATHOLOGY  Neoplasms/*THERAPY  THESIS

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).